Rolf Stahel

Rolf Stahel FRSA (born 21 April 1944) is a Swiss businessman who was CEO of Shire Pharmaceuticals from March 1994 to March 2003, transforming it from a private $30 million company into a member of the FTSE 100.[1][2]

He attended the Advanced Management Program at Harvard Business School.[3]

He was Non-executive Chairman of EUSA Pharma from 2007 to 2012,[3] prior to its acquisition by Jazz Pharmaceuticals for $650 million.[4] He is currently Non-executive Chairman of Midatech Pharma PLC,[5] and founder Chairman of consultancy services firm Chesyl Pharma Ltd.[6]

He is a Fellow of the Royal Society of Arts and a member of the Royal Automobile Club.[3]

References

  1. ↑ "Shire chief's $10m 'golden hello' at AbbVie". Financial Times. Retrieved 28 March 2018.
  2. ↑ "Executive Profile: Rolf Stahel". Bloomberg L.P. Retrieved 28 March 2018.
  3. 1 2 3 "Stahel, Rolf, (born 21 April 1944), Chairman, Chesyl Pharma Ltd, since 2003; non-executive Chairman: Midatech Pharma plc, since 2014; Ampha Ltd, since 2016." WHO'S WHO & WHO WAS WHO. 28 Mar. 2018.
  4. ↑ "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
  5. ↑ "Board of Directors". Midatech Pharma. Retrieved 28 March 2018.
  6. ↑ "Advisory Board". Imperial College Business School. Retrieved 30 March 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.